96955 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons Tumour necrosis factor [TNF]
Sub-classes:HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#2SINGLE-CHAIN TNF RECEPTOR 2 AGONIST FUSION PROTEINS
#3TNF-ALPHA VARIANT FUSION MOLECULES
#4HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#5Enhanced adoptive cell therapy
#6ANTI-TNF-ALPHA POLYPEPTIDE COMPOSITION AND USE THEREOF
#7REGULATION OF IMMUNE RESPONSES THROUGH SELECTIVE NEURAL ACTIVATION
#8HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#9HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#10IMMUNOMODULATORY FUSION PROTEIN-METAL HYDROXIDE COMPLEXES AND METHODS THEREOF
#11METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG
#12TARGETED MODIFIED TNF FAMILY MEMBERS
#13CYTOKINE COMPOSITIONS AND METHODS OF USE THEREOF
#14BLOCKADE OF CD3 EXPRESSION AND CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY
#15Methods and compositions for improving the immune response against viral pathogens
#16METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS
#17Pharmaceutical Composition for Preventing and Treating Liver Disease Comprising Novel Peptide
#18MULTIVALENT PROTEINS AND SCREENING METHODS
#19CHIMERIC ANTIGEN RECEPTOR MODIFIED REGULATORY T CELLS FOR TREATING CANCER
#20HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#21DOMINANT-NEGATIVE TUMOR NECROSIS FACTOR ALPHA ADENO-ASSOCIATED VIRUS GENE THERAPY
#22ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents
#23IL-2 AND TL1A FUSION PROTEINS AND METHODS OF USE THEREOF
#24TNF-ALPHA VARIANT FUSION MOLECULES
#25MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#26RNA CONSTRUCT
#27Dendritic Cell Generator
#28CYTOKINE COMPOSITIONS AND METHODS OF USE THEREOF
#29MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#30MECHANISM OF ACTION
#31SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#32PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS
#33MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#34ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST
#35SPLIT HUMAN IFN-GAMMA AND TNF-ALPHA CONSTRUCTS AND USES THEREOF
#36TRIMERIC ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS
#37METHODS OF MAKING AND USING EXTRACELLULAR DOMAIN-BASED CHIMERIC PROTEINS
#38STABLE LIQUID FORMULA
#39EARLY DETECTION OF INNATE IMMUNE DYSFUNCTION AND TREATMENT OF CONDITIONS ASSOCIATED THEREWITH
#40MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOF
#41MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#42MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
#43METHODS FOR INDUCING AN IMMUNE RESPONSE BY ADMINISTERING ACTIVATED MESENCHYMAL STEM CELLS
#44ATP-dependent agonists of immune cells function as anticancer agents
#45A SUPER-TRAIL MOLECULE COMPRISING TWO TRAIL TRIMERS
#46MODIFIED TNF AS A CAPTURE LIGAND
#47ANTIBODIES TARGETING BAFF-R AND USE THEREOF
#48TNFR2 agonists with improved stability
#49Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
#50TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS
#51BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS
#52ADENOVIRUS FOR TREATMENT OF CANCER
#53MODIFICATION OF IMMUNE CELLS FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
#54MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
#55An oncolytic virus vector coding for variant interleukin-2 (vIL-2) polypeptide
#56Cancer Treatment
#57SINGLE-CHAIN TNF RECEPTOR 2 AGONIST FUSION PROTEINS
#58REGULATION OF IMMUNE RESPONSES THROUGH SELECTIVE NEURAL ACTIVATION
#59METHODS AND COMPOSITIONS COMPRISING FUSION PROTEINS FOR THE IDENTIFICATION OF IMMUNOTHERAPY CELLS
#60ANTIGEN BINDING POLYPEPTIDE COMPLEXES CONTAINING EXTRACELLULAR DOMAINS OF TNFSF LIGANDS
#61THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES
#62PHARMACEUTICAL METHOTREXATE COMPOSITION
#63VIRUSES ENGINEERED TO PROMOTE THANOTRANSMISSION AND THEIR USE IN TREATING CANCER
#64MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
#65UNIVERSAL DONOR CELLS
#66MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
#67IMMUNOMODULATORY FUSION PROTEIN-METAL HYDROXIDE COMPLEXES AND METHODS THEREOF
#68ENHANCED-AFFINITY ANTI-ECM NANOBODY-CYTOKINE FUSIONS AND THEIR APPLICATIONS
#69BI-FUNCTIONAL CHIMERIC PROTEINS AND USES THEREOF
#70Cancer prevention and therapy by inhibiting soluble tumor necrosis factor
#71COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF
#72Fusion protein comprising an antigen binding domain and a cytokine trimer domain
#73T cell-antigen coupler with Y182T mutation and methods of uses thereof
#74A FUSION PROTEON OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) AND INTERLEUKIN-2 (IL-2) AND APPLICATIONS THEREOF
#75Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
#76COLLAGEN-TARGETED FUSION PROTEINS AND ANTIBODIES
#77MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
#78AUGMENTING ANTIGEN-NEGATIVE CELL DEATH IN ANTIGEN-TARGETED IMMUNOTHERAPIES
#79MODULATOR ASSAY
#80UNIVERSAL DONOR CELLS
#81UNIVERSAL DONOR CELLS
#82POLYMERIC NANOPARTICLES PROVIDING NUCLEIC ACIDS ENCODING TNF-a
#83Fusion Protein Extensions
#84METHODS OF TREATING NEUROLOGICAL DISEASES
#85UNIVERSAL DONOR CELLS
#86Dendritic cell generator
#87ANAPLASTIC LYMPHOMA KINASE CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
#88FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES
#89Adeno-Associated Viral (AAV) Vectors for Tissue-Targeted Expression of Therapeutic Genes
#90HUMANIZED TRANSGENIC ANIMAL
#91INTERLEUKIN-2 IN COMBINATION WITH TNF RECEPTOR FAMILY MEMBERS FOR THE EXPANSION OF T-REGULATORY CELLS
#92NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA
#93COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS
#94NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS
#95FUSION PROTEINS THAT FACILITATE CANCER CELL DESTRUCTION
#96PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF
#97Modified TNF as a capture ligand
#98TNF MUTEINS AND USES THEREOF
#99GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TNFR2
#100FIBROBLAST ACTIVATION PROTEIN BINDING AGENTS AND USE THEREOF
#101Methods of prognosis and treatment
#102SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#103MULTIMERIC PROTEIN DOMAINS FOR MULTIFUNCTIONALITY AND ENHANCED SECRETION OF THERAPEUTIC PROTEINS
#104Targeted modified TNF family members
#105Methods of making and using extracellular domain-based chimeric proteins
#106CHIMERIC PROTEINS IN AUTOIMMUNITY
#107SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS
#108Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof
#109SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS
#110TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS
#111Universal donor cells
#112Universal donor cells
#113CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF
#114NOVEL BIOMOLECULE CONJUGATES AND USES THEREFOR
#115METHODS FOR REDUCING POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD)
#116TUMOR NECROSIS FACTOR SUPERFAMILY AND TNF-LIKE LIGAND MUTEINS AND METHODS OF PREPARING AND USING THE SAME
#117ANTIBODY-TUMOR NECROSIS FACTOR alpha FUSION PROTEIN AND ITS PREPARATION AND APPLICATIONS
#118Methods of use of anti-TNFα antibodies
#119SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS
#120SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS
#121SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS
#122SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS
#123CHIMERIC ANTIGEN RECEPTORS COMPRISING BCMA-SPECIFIC FIBRONECTIN TYPE III DOMAINS AND USES THEREOF
#124SUICIDE GENE
#125Protein signatures for distinguishing between bacterial and viral infections
#126Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases
#127Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
#128A NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS
#129Arginine-free TNFR:FC-fusion polypeptide compositions
#130MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#131T cell-antigen coupler with Y177 mutation and methods of uses thereof
#132HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#133IMMUNE-MEDIATED CORONAVIRUS TREATMENTS
#134Methods of treating cancer with TNF expressing myxoma virus
#135Therapeutic targeting of non-cellular structures
#136ALLOGENEIC TUMOR CELL VACCINE
#137Methods for inducing an immune response by administering activated mesenchymal stem cells
#138Methods of administering mesenchymal stem cells activated by cytokines for enhancing immunosuppression
#139Stable liquid formula comprising anti-TNFa antibody, acetate buffer, and glycine
#140Method for detecting castration-resistant prostate cancer and detection reagent
#141ANTIBODIES ANTI TUMOR ASSOCIATED ANTIGENS AND METHOD FOR OBTAINING THEM
#142System and method for removal of immune inhibitors from biological fluids
#143SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS
#144MECHANISM OF ACTION
#145The IgM and IgE Heavy Chain Domain 2 as Covalently Linked Homodimerization Modules for the Generation of Fusion Proteins with Dual Specificity
#146ANTIBODY
#147MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#148Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
#149Fusion Proteins Containing CD47 Antibodies and Cytokines
#150Method of identifying potential inhibitors of APO TNFα trimers
#151IN VIVO PRODUCTION OF PROTEINS
#152Humanized transgenic animal
#153Oncolytic virus platform to treat cancers with myxoma virus
#154Antibodies to tumour antigens
#155Cytokine fusion proteins
#156COMBINATION THERAPY USING A CHIMERIC ANTIGEN RECEPTOR
#157Serpin fusion polypeptides and methods of use thereof
#158Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
#159Serpin fusion polypeptides and methods of use thereof
#160Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
#161Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptors
#162Enhanced adoptive cell therapy
#163TIGIT- and light-based chimeric proteins
#164T cell-antigen coupler with Y182T mutation and methods and uses thereof
#165Dendritic cell generator
#166METHODS OF REGULATORY T CELL EXPANSION AND ACTIVATION
#167Single-chain TNF receptor 2 agonist fusion proteins
#168MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#169Compositions containing HC-HA/PTX3 complexes and methods of use thereof
#170Method for treating complications related to acute or chronic hyperglycemia
#171TIGIT- and light-based chimeric proteins
#172ANTIGEN BINDING MOLECULES COMPRISING A TRIMERIC TNF FAMILY LIGAND
#173ANTIBODIES AGAINST PHOSPHORYLCHOLINE IN COMBINATION THERAPY WITH BIOLOGIC AGENTS
#174Targeted modified TNF family members
#175MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#176Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells
#177Cancer treatment
#178Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
#179Methods of making and using extracellular domain-based chimeric proteins
#180METHODS OF TREATING NEUROLOGICAL DISEASES
#181Mutant human estrogen receptor-α and methods of use thereof
#182Method for producing monomeric and multimeric molecules and uses thereof
#183Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#184GITRL FUSION PROTEINS AND USES THEREOF
#185Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers
#186Anti-tumor T cells and their preparation using IL-6
#187Methods for reducing post-operative cognitive dysfunction (POCD)
#188Serpin fusion polypeptides and methods of use thereof
#189Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
#190SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#191Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
#192Cancer prevention and therapy by inhibiting soluble tumor necrosis factor
#193Nanobodies against tumor necrosis factor-alpha
#194ANTI-TNF-ALPHA POLYPEPTIDE COMPOSITION AND USE THEREOF
#195PANTIDS FOR TREATMENT OF AUTOIMMUNE DISORDERS
#196Modified polynucleotides for the production of secreted proteins
#197TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS
#198Targeted modified TNF family members
#199BCMA-targeting antibody and use thereof
#200TISSUE-BASED BIOLOGICS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISORDERS
#201METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS
#202Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine
#203Cancer prevention and therapy by inhibiting soluble tumor necrosis factor
#204Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
#205Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
#206Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof
#207PD-L1 AND PD-L2-BASED FUSION PROTEINS AND USES THEREOF
#208Polymeric nanoparticles providing nucleic acids encoding TNF-α
#209Modified polynucleotides for the production of secreted proteins
#210In vivo production of proteins
#211COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS
#212USE OF DNA NETOSIS TO DELIVER TRAIL FOR CANCER THERAPY
#213IL2 and TNF immunoconjugates
#214Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligands
#215Methods of prognosis and treatment
#216CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS
#217Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety
#218MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
#219CD40L single-chain fusion polypeptides and encoding nucleic acids
#220Compositions containing HC-HA/PTX3 complexes and methods of use thereof
#221Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
#222Bi-functional chimeric proteins and uses thereof
#223Protein for neutralizing programmed necrocytosis promotion antibody, and application of protein
#224Protein signatures for distinguishing between bacterial and viral infections
#225Polypeptides and uses thereof for reducing CD95-mediated cell motility
#226Mesenchymal Stem Cells Expressing Biomarkers that Predict the Effectiveness of Mesenchymal Stem Cells for Treating Diseases and Disorders
#227Methods of producing activated mesenchymal stem cells
#228METHODS RELATING TO ACTIVATED DENDRITIC CELL COMPOSITIONS AND IMMUNOTHERAPEUTIC TREATMENTS FOR SUBJECTS WITH ADVANCED CANCERS
#229CD27 ligand (CD27L) single-chain fusion polypeptides
#230NOVEL BIOMOLECULE CONJUGATES AND USES THEREFOR
#231CD27L collectin fusion proteins and encoding nucleic acids
#232TRIMERIC COSTIMULATORY TNF FAMILY LIGAND-CONTAINING ANTIGEN BINDING MOLECULES
#233Fusokines involving cytokines with strongly reduced receptor binding affinities
#234RNA molecules encoding cytokine fusion proteins and methods of use thereof
#235Compositions and methods for treating opioid tolerance
#236MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES
#237ERYTHROFERRONE AND ERFE POLYPEPTIDES AND METHODS OF REGULATING IRON METABOLISM
#238Chimeric antigen receptor cell preparation and uses thereof
#239Method of manufacturing a protein by perfusion in media with a low amino acid concentration
#240Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
#241Modified Polynucleotides for the production of biologics and proteins associated with human disease
#242Targeted modified TNF family members
#243PROTEIN CONJUGATES
#244Method for mass producing proteins in mesenchymal stem cells
#245Kit for immunological detection of TNF-alpha, sTNFR1 and IL-8 in prostate cancer
#246Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers
#247Method for in vivo expansion of T regulatory cells
#248Methods of identifying signaling modulators of the trimeric TNFa
#249Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#250Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#251Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.
#252Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#253Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#254Antibodies against phosphorylcholine in combination therapy with biologic agents
#255Nucleic acids encoding artificial signal peptides and methods of production thereof
#256Allogeneic tumor cell vaccine
#257Serpin fusion polypeptides and methods of use thereof
#258TNF receptor signaling modulator assay
#259Antibodies binding to trimeric TNF alpha epitopes
#260Dendritic cell generator
#261Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding them
#262MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
#263Targeted modified TNF family members
#264Fusokines involving cytokines with strongly reduced receptor binding affinities
#265CANCER IMMUNOTHERAPEUTIC
#266Oncolytic virus therapy for resistant tumors
#267Fusion proteins that facilitate cancer cell destruction
#268Antibodies against phosphorylcholine in combination therapy with biologic agents
#269Hydroxyl purine compounds and use thereof
#270MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#271IL2 and TNF immunoconjugates
#272Recombinant TNF ligand family member polypeptides with antibody binding domain and uses thereof
#273PD-L1 and PD-L2-based fusion proteins and uses thereof
#274CONJUGATE AND USE THEREOF
#275Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide, methods and uses therefor
#276Compositions and methods of using a soluble TNF-alpha receptor modified for increased half-life
#277Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
#278Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides
#279Modified polynucleotides for the production of oncology-related proteins and peptides
#280Cytokine fusion proteins
#281Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#282CHEMICALLY AND THERMODYNAMICALLY STABLE INSULIN ANALOGUES AND IMPROVED METHODS FOR THEIR PRODUCTION
#283LOW ACIDIC SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME USING DISPLACEMENT CHROMATOGRAPHY
#284In vivo production of proteins
#285NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA
#286Method for producing monomeric and multimeric molecules and uses thereof
#287Ligand
#288PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER BINDING PROTEINS
#289Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
#290IgM and IgE heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
#291Chemokine-cytokine fusion proteins of SDF-1 and CD40L
#292COMPOSITIONS AND METHODS FOR LONG ACTING PROTEINS
#293Glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) single-chain fusion polypeptides
#294CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF
#295METHOD OF USING A PEPTIDE LIBRARY
#296Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
#297INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
#298PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER BINDING PROTEINS
#299Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
#300Co-expression plasmid